Bio-Techne

TECH · NASDAQ

$72.58+$0.09 (+0.12%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $72.49

TECH analyst rating

HoldConsensus of 13 analysts over the last 12 months. 15% rate it a buy.

Strong buy0
Buy2
Hold11
Underperform0
Sell0

12-month price target · 14 analysts

Average $71.42 (−1.6% downside)

Low: $50.50
Now: $72.58
High: $78.75

Upgrades and downgrades

The latest rating actions, newest first

TECH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Aug 13, 2026	Downgrade	Overweight → Equal-Weight	$62.00 → $73.00	100%
RBC Capital	Jul 9, 2026	Downgrade	Outperform → Sector Perform	$62.00 → $73.00	59%
TD Cowen	Jun 30, 2026	Downgrade	Buy → Hold	$65.00 → $73.00	100%
Benchmark	Jun 30, 2026	Downgrade	Buy → Hold	—	53%
Citigroup	Jun 29, 2026	Downgrade	Buy → Neutral	$70.00 → $73.00	55%
Stephens & Co.	Jun 26, 2026	Downgrade	Overweight → Equal-Weight	$68.00 → $73.00	75%
William Blair	Jun 26, 2026	Downgrade	Outperform → Market Perform	—	50%
Baird	Jun 26, 2026	Maintains	Neutral	$49.00 → $73.00	61%
Piper Sandler	Jun 11, 2026	Initiates	Neutral	$65.00	58%
RBC Capital	May 15, 2026	Initiates	Outperform	$62.00	59%

The case for and against

Updated Oct 18, 2026

Bull case

Bio-Techne is supported by a best-in-class protein reagents franchise and a diagnostics/genomics portfolio that benefits from durable demand in pharma, biotech, academic, and diagnostic markets, with ~20% of sales tied to private/SMID biotech and ~15% exposure to cell therapy after Wilson Wolf. The company also appears well positioned for a funding recovery, as biotech VC, IPO, and secondary activity more than tripled year-to-date year over year through April, which should eventually support demand for its consumables and instruments. Fundamentally, self-help actions such as divesting Exosome Diagnostics and consolidating brands from 10 to 3 should aid margins, while the planned Wilson Wolf acquisition adds growth, high EBITDA margins, and a strategic fit in cell therapy manufacturing.

Bear case

Bio-Techne is facing a negative setup because its core life-science tools markets have still not normalized, and the company has already suffered years of false starts in demand recovery. Its protein sciences business, which drives about 75% of revenue, is exposed to wet-lab research demand that could be structurally pressured if software and AI reduce experiment volume, while diagnostics and genomics also face execution and adoption risk. Competitive pressure is intensifying as key rivals like PeproTech, Abcam, and BioLegend have been acquired by larger players, and with cell therapy tied to roughly 15% of sales, any disappointment there could amplify multiple compression and share loss concerns.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.